The Core of the TheraMe! strength is its unique
Technology

Targeted data
Fast results
affordable screening
400+ therapy options

We make personalized therapy possible

The main problem in cancer therapy is that every patient and every tumor is different and reacts differently to drugs. Even worse, tumor cells rapidly change their response to drugs over time and develop resistances. What is needed is a system allowing to test which drug or drug combination works best on the tumor cells of a given patient at a given point in time. This is exactly the concept of TheraMe! We use microfluidic technology (a kind of miniaturized laboratory on a chip) to determine the best therapy options directly on live tumor samples from patients.

Read more in these high impact publications

What makes us unique

By using proprietary microfluidic technology we can run many drug tests directly on the tumor cells from patient biopsies or tumor resections. Instead of using conventional test tubes or microtiter plates, which require more cells for drug screens than what can be obtained from a patient, we perform drug tests in microscopic droplets inside microfluidic systems. Our approach has manifold advantages over existing technology:

1
High throughput, independent of biomarker availability

In contrast to companion diagnostic tests we cannot only test the response to individual drugs, but rather to hundreds of treatment options in a single screen. Furthermore, we are fully target agnostic, meaning we do not need any prior knowledge on biomarkers of a given tumor and we provide direct evidence for drug response, not just probabilities.

2
Affordability and rapid turnover

Using our system, the best therapy option for each patient can be determined within 24h at a market price of ~1500 US$ per patient screen, which is similar to routine diagnostic tests and fully compatible with clinical needs and decision making.

3
Pre-therapy analysis

In contrast to counting circulating tumor cells (CTCs) for personalized therapy purposes, we provide data on drug response even before the therapy starts and for hundreds of possible drug treatments simultaneously. This way patients do not have to undergo painful therapies that later on turn out to be inefficient.


Intelectual Property
TheraMe! has a comprehensive patent portfolio

The core technology of the TheraMe! approach is covered by a granted US patent (US20140332083A1). Furthermore, we have filed three more patent applications on additional technology protecting future developments (EP14186463.7, EP15174088.3 and EP 21170297.2). Taken together, TheraMe! has a comprehensive patent portfolio, putting it in a unique position to offer microfluidics-guided personalized medicine approaches.

FTO
Green light for commercial exploitation of the TheraMe! approach

The FTO analysis carried out by a professional patent law firm showed that the commercial use of droplet microfluidic systems as used in the TheraMe! platform is likely not to be dependent on other patents than our own proprietary technology.